
Opinion|Videos|January 20, 2025
Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
American Cancer Society Updates Prostate Cancer Screening Guidelines
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
5

